Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2007-12-18
2007-12-18
Canella, Karen A. (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S198100
Reexamination Certificate
active
10295600
ABSTRACT:
The present invention discloses protocols for HER cancers that are also endocrine dependent in a manner that provides dual action by using both HER antibodies and endocrine blockers/downregulators and insures function of S-Phase cytotoxics by administration of endocrines prior to administration of the S-Phase cytotoxic.
REFERENCES:
patent: WO 96/40284 (1996-12-01), None
Jain, Scientific American, 1994, vol. 271, pp. 58-65.
O'Quinn et al (Gynecologic Oncology, 1984, vol. 18, pp. 135-144).
the abstract of Rossi et al (Blood, 2000, vol. 96, pp. 326a-327a).
Aglietta et al (Leukemia. 1991 vol. 11, pp. 979-984).
Pegram et al. Oncogene, 1999, 18, 2241-2251.
Barranco et al (Cancer Research, 1982, vol. 42, pp. 2899-2905).
Bunn et al, Clinical Cancer Research, Oct. 2001, vol. 7, pp. 3239-3250.
Cooper, “Oncogenes”, 1995, p. 203.
Herceptin (trastuzumab) Full Prescribing Information, Nov. 2006 Revision, Genentech Inc.
Harrison's Principles of Internal Medicine, Braunwald et. al., 15th edition, McGraw Hill, 2001 , pp. 530-531, 538-541.
Harrison's Principles of Internal Medicine, Fauci et. al., 14th edition, McGraw Hill, 1998 , pp. 527-536.
Molecular Biology of the Cell, Alberts et. al. Third Edition, Garland Publishing, 1994, pp. 896-897, 898.
Herceptin® Trastuzumab, Full Prescribing Information, Genentech, Inc., FDA revision Aug. 2002.
Zamoyski, Mark, “Cell Cycle Synchronous Chemotherapy”, presentation / seminar handout at Stanford Genome Technology Center, 855 California Ave, Palo Alto, CA,Sep. 2, 2004.
Science News, Aug. 11, 2001 vol. 160, p. 89, “Chemotherapy leads to bone loss” by Damaris Christensen.
Fonagy et. al. , “The effect of . . . galactitiol on RNA synthesis . . . ”, Acta Biochim Biophys Acad Sci Hung., 1981; 16(3-4):151-62.
LandOfFree
HER cancer protocols does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with HER cancer protocols, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HER cancer protocols will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3834652